These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 59627)

  • 1. A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia.
    Levi JA; Wiernik PH
    Cancer; 1976 Jul; 38(1):36-41. PubMed ID: 59627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of 5-azacytidine as induction for acute nonlymphocytic leukemia in patients with previous exposure to 5-azacytidine.
    Gaynon PS; Baum ES
    Oncology; 1983; 40(3):192-4. PubMed ID: 6189042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-azacytidine in refractory acute leukemia.
    Case DC
    Oncology; 1982; 39(4):218-21. PubMed ID: 6178065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-azacytidine in acute leukemia.
    Saiki JH; McCredie KB; Vietti TJ; Hewlett JS; Morrison FS; Costanzi JJ; Stuckey WJ; Whitecar J; Hoogstraten B
    Cancer; 1978 Nov; 42(5):2111-4. PubMed ID: 82472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanazole (NSC-1895)--a phase I clinical study.
    Caoili EM; Talley RW; Smith F; Salem P; Vaitkevicius VK
    Cancer Chemother Rep; 1975; 59(6):1117-21. PubMed ID: 769950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study.
    Saiki JH; Bodey GP; Hewlett JS; Amare M; Morrison FS; Wilson HE; Linman JW
    Cancer; 1981 Apr; 47(7):1739-42. PubMed ID: 6164472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.
    Wiernik PH; Schimpff SC; Schiffer CA; Lichtenfeld JL; Aisner J; O'Connell MJ; Fortner C
    Cancer Treat Rep; 1976 Jan; 60(1):41-53. PubMed ID: 1069608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical trial of pyrazofurin in combination with 5-azacytidine in acute adult nonlymphocytic leukemia.
    Van Echo DA; Chiuten DF; Markus S; Wiernik PH
    Cancer Clin Trials; 1981; 4(2):129-33. PubMed ID: 6166406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility and efficacy of 5-azacytidine used early in the therapy of adult acute nonlymphocytic leukemia: an ECOG pilot study.
    Cassileth PA; Petrillo MH; Cooper RA; Katz ME
    Cancer Clin Trials; 1979; 2(4):339-43. PubMed ID: 93983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia.
    Lee EJ; Hogge DE; Gallagher R; Schiffer CA
    Leukemia; 1990 Dec; 4(12):835-8. PubMed ID: 1700839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine.
    Look AT; Dahl GV; Kalwinsky D; Senzer N; Mason C; Rivera G
    Cancer Treat Rep; 1981; 65(11-12):995-9. PubMed ID: 6170431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.
    Lübbert M; Bertz H; Wäsch R; Marks R; Rüter B; Claus R; Finke J
    Bone Marrow Transplant; 2010 Apr; 45(4):627-32. PubMed ID: 19718057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-azactidine and zorubicin for patients with previously treated acute nonlymphocytic leukemia: a Cancer and Leukemia Group B pilot study.
    Peterson BA; Bloomfield CD; Gottlieb AJ; Coleman M; Greenberg MS
    Cancer Treat Rep; 1982 Mar; 66(3):563-6. PubMed ID: 6174230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with 5-azacytidine (NSC-102816) and methyl-GAG (NSC-32946) in previously treated adults with acute nonlymphocytic leukemia.
    Levi JA; Wiernik PH
    Cancer Chemother Rep; 1975; 59(5):1043-5. PubMed ID: 54215
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of refractory adult acute nonlymphoblastic leukemia with subcutaneous 5-azacytidine.
    Armitage JO; Burns CP
    Cancer Treat Rep; 1977 Dec; 61(9):1721-3. PubMed ID: 74285
    [No Abstract]   [Full Text] [Related]  

  • 16. Guanazole in the treatment of advanced bronchogenic carcinoma: a pilot study of the Southeastern Cancer Study Group.
    Krauss S; Broder LE; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):913-4. PubMed ID: 3719585
    [No Abstract]   [Full Text] [Related]  

  • 17. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of pyrazofurin and 5-azacytidine in refractory adult acute leukemia.
    Martelo OJ; Broun GO; Petruska PJ
    Cancer Treat Rep; 1981; 65(3-4):237-9. PubMed ID: 6165467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
    Wilhelm M; O'Brien S; Rios MB; Estey E; Keating MJ; Plunkett W; Sorenson M; Kantarjian HM
    Leuk Lymphoma; 1999 Aug; 34(5-6):511-8. PubMed ID: 10492074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.